Though FFA2 and FFA3 are mechanistically unstudied in cats to the authors’ knowledge, a GLP-1 analogue has been shown to promote weight loss in diabetic cats compared to placebo[46], and FFA2 and FFA3 targeted therapeutics are of growing interest in type 2 diabetes in people given their roles in regulating insulin sensitivity and expression in pancreatic β cells[5, 47]. The gene discussed is INS; the disease is type 2 diabetes mellitus.